Debiopharm said Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours, including resistance to chemotherapy.
Aurigene CEO CSN Murthy said coming as it does after a successful collaboration programme they already had with Debiopharm, and as a continuation of their close to 5 year association, the relationship between Debiopharm and Aurigene demonstrates the strategic fit between organisations with complimentary scientific skills.